CTLA4 and renal cell carcinoma: Combination of anti-CTLA4 and anti-PD1 antibodies were effective in melanoma, renal cell carcinoma, and microsatellite instability-high (MSI-H) colorectal cancers [36], and concomitant blockade of CTLA4 and PD1 increased production of IFNγ from CD8+ cells [37].